Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience
- PMID: 8520875
- DOI: 10.1007/BF00335305
Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience
Abstract
A high incidence of bacterial infections has been previously reported during interleukin-2 (IL-2) treatment, mainly due to catheter-related infections. Antibiotic prophylaxis has been successfully used to decrease such infections. The goal of this study was to evaluate an alternative way to reduce catheter-related infections in IL-2-treated patients by the use of totally implanted catheters. A total of 74 patients with metastatic renal cell carcinoma, referred to our institution to receive IL-2 from March 1989 to July 1991, were included in this prospective study. IL-2 was given on a 2-days-a-week schedule (24 x 10(6) IU m-2 day-1) either alone (41 patients) or in association with interferon gamma (33 patients). All these patients were prospectively evaluated for fever, bacteremia and line-site infection. Seven patients (9.5%) had one (2 patients) or more (5 patients) positive blood cultures with Staphylococcus aureus. Antibiotics were used only in 5 patients, and the catheter had to be removed in only 2 of these patients. In the other patients, no further infection developed despite the lack of antibiotics. Moreover, 9 patients had positive blood cultures with Staphylococcus epidermidis (1.9% of total number of blood cultures). In conclusion, a totally implanted catheter appears to reduce the incidence of infections in IL-2-treated patients, at least on a 2-days-a-week schedule.
Similar articles
-
A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2.Cancer. 1998 Jan 15;82(2):403-11. doi: 10.1002/(sici)1097-0142(19980115)82:2<412::aid-cncr22>3.0.co;2-0. Cancer. 1998. PMID: 9445199 Clinical Trial.
-
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy.J Clin Oncol. 1990 Jan;8(1):161-9. doi: 10.1200/JCO.1990.8.1.161. J Clin Oncol. 1990. PMID: 2404087 Clinical Trial.
-
[Infectious and non-infectious complications of tunneled central catheters in hematologic patients].Sangre (Barc). 1999 Jun;44(3):176-81. Sangre (Barc). 1999. PMID: 10481577 Spanish.
-
The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2.Int J Infect Dis. 2010 Jul;14(7):e548-52. doi: 10.1016/j.ijid.2009.08.007. Epub 2009 Dec 14. Int J Infect Dis. 2010. PMID: 20005762 Review.
-
Catheter-associated Staphylococcus aureus bacteremia.Hosp Pract (1995). 1996 Sep 15;31(9):133-7, 142-4, 150. doi: 10.1080/21548331.1996.11443351. Hosp Pract (1995). 1996. PMID: 8814127 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical